JP2009530415A5 - - Google Patents

Download PDF

Info

Publication number
JP2009530415A5
JP2009530415A5 JP2009501678A JP2009501678A JP2009530415A5 JP 2009530415 A5 JP2009530415 A5 JP 2009530415A5 JP 2009501678 A JP2009501678 A JP 2009501678A JP 2009501678 A JP2009501678 A JP 2009501678A JP 2009530415 A5 JP2009530415 A5 JP 2009530415A5
Authority
JP
Japan
Prior art keywords
solid dispersion
pharmaceutical composition
polymer
surfactant
multiple polymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009501678A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009530415A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/064293 external-priority patent/WO2007109604A2/en
Publication of JP2009530415A publication Critical patent/JP2009530415A/ja
Publication of JP2009530415A5 publication Critical patent/JP2009530415A5/ja
Pending legal-status Critical Current

Links

JP2009501678A 2006-03-20 2007-03-19 医薬組成物 Pending JP2009530415A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78442806P 2006-03-20 2006-03-20
PCT/US2007/064293 WO2007109604A2 (en) 2006-03-20 2007-03-19 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JP2009530415A JP2009530415A (ja) 2009-08-27
JP2009530415A5 true JP2009530415A5 (enExample) 2011-04-28

Family

ID=38523221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009501678A Pending JP2009530415A (ja) 2006-03-20 2007-03-19 医薬組成物

Country Status (11)

Country Link
US (4) US20070218138A1 (enExample)
EP (1) EP2001498A4 (enExample)
JP (1) JP2009530415A (enExample)
CN (1) CN101494979A (enExample)
AR (1) AR059978A1 (enExample)
AU (1) AU2007226983A1 (enExample)
CA (1) CA2645566A1 (enExample)
PE (2) PE20110286A1 (enExample)
TW (1) TW200812611A (enExample)
UY (1) UY30226A1 (enExample)
WO (1) WO2007109604A2 (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79749C2 (en) 1996-10-18 2007-07-25 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
WO2007002433A1 (en) * 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AU2007217355B2 (en) 2006-02-27 2012-06-21 Vertex Pharmaceuticals Incorporated Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
EP2194039A1 (en) 2006-03-16 2010-06-09 Vertex Pharmceuticals Incorporated Process for preparing optically enriched compounds
ES2882684T3 (es) 2006-04-07 2021-12-02 Vertex Pharma Preparación de moduladores de transportadores del casete de unión a ATP
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CN101903392A (zh) 2007-02-27 2010-12-01 弗特克斯药品有限公司 丝氨酸蛋白酶的抑制剂
CA2679312A1 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
BRPI0814423B1 (pt) 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
WO2009032198A1 (en) 2007-08-30 2009-03-12 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
AU2009223014A1 (en) * 2008-03-11 2009-09-17 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
AU2009226019C1 (en) 2008-03-20 2014-02-20 Virun, Inc. Emulsions including a PEG-derivative of tocopherol
CN103190631B (zh) 2008-03-20 2016-01-20 维尔恩公司 非水性预乳液组合物及制备包含植物甾醇的饮料的方法
AU2009256623A1 (en) * 2008-06-10 2009-12-17 Janssen Pharmaceutica Nv Telaprevir dosing regimen
GB0815852D0 (en) 2008-09-01 2008-10-08 Unilever Plc Improvements relating to pharmaceutical compositions
CA2737481A1 (en) * 2008-09-16 2010-03-25 Douglas Ludtke Stable solid oral dosage co-formulations
EP2396028A2 (en) 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
MX2011008303A (es) 2009-04-03 2011-11-29 Plexxikon Inc Composiciones del acido propano-1-sulfonico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil}-amida y el uso de las mismas.
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
BR112012012156A2 (pt) 2009-11-06 2015-09-08 Plexxikon Inc compostos e métodos para modulação de cinase, e indicações para esta
WO2011094489A1 (en) 2010-01-29 2011-08-04 Vertex Pharmaceuticals Incorporated Therapies for treating hepatitis c virus infection
CN103037708B (zh) 2010-03-23 2015-05-20 维尔恩公司 含有蔗糖脂肪酸酯的纳米乳液
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2845449T3 (es) * 2010-03-25 2021-07-26 Vertex Pharma Dispersión sólida de forma amorfa de (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-il)-N-(1-(2,3-dihidroxipropil)-6-fluoro-2(1-hidroxi-2-metilpropan-2-il)-1h-indol-5il)-ciclopropanocarboxamida
RU2569678C2 (ru) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
WO2011152297A1 (ja) * 2010-05-31 2011-12-08 アステラス製薬株式会社 トリアゾール化合物の固体分散体
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
AR082215A1 (es) 2010-07-14 2012-11-21 Vertex Pharma Composicion farmaceutica agradable al paladar
CA2815416A1 (en) 2010-10-21 2012-04-26 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
TWI558400B (zh) * 2011-03-18 2016-11-21 艾伯維有限公司 苯基尿嘧啶化合物之調配物
US9180099B2 (en) * 2011-07-07 2015-11-10 Arqule Inc. Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
EP2578974A1 (en) * 2011-10-05 2013-04-10 Sanofi Pasteur Sa Process line for the production of freeze-dried particles
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
EP2907505A3 (en) * 2011-12-29 2015-12-30 Abbvie Inc. Solid compositions comprising an HCV inhibitor
WO2013116339A1 (en) 2012-01-31 2013-08-08 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
WO2013120025A1 (en) 2012-02-10 2013-08-15 Virun, Inc. Beverage compositions containing non-polar compounds
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EA201492082A1 (ru) 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
WO2014015217A1 (en) 2012-07-19 2014-01-23 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
WO2014096343A1 (en) * 2012-12-21 2014-06-26 Sandoz Ag Novel forms of telaprevir
KR20200060782A (ko) 2013-01-31 2020-06-01 길리애드 파마셋 엘엘씨 두 항바이러스 화합물의 병용 제형물
CA2903831A1 (en) 2013-03-15 2014-09-25 Boehringer Ingelheim International Gmbh Solid oral dosage formulation of hcv inhibitor in the amorphous state
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
CA2935307C (en) * 2013-12-31 2023-05-09 Ascendia Pharmaceuticals, Llc Pharmaceutical compositions for poorly water-soluble compounds
PT3131582T (pt) 2014-04-15 2018-10-08 Vertex Pharma Composições farmacêuticas para o tratamento de doenças mediadas pelo regulador de condutância transmembranar da fibrose quística
EP3193877A4 (en) * 2014-08-07 2018-04-04 Pharmacyclics LLC Novel formulations of a bruton's tyrosine kinase inhibitor
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
CN106620711B (zh) * 2015-11-03 2019-06-25 中国科学院大连化学物理研究所 一种含有白藜芦醇的组合物及其制备方法
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
EP4552641A3 (en) * 2016-05-09 2025-07-30 AustinPx, LLC Improved drug formulations
CN110072525B (zh) 2016-09-30 2022-12-02 萨利克斯药品公司 利福昔明的固态分散形式
IL297717A (en) 2016-12-01 2022-12-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
WO2019134971A1 (en) * 2018-01-04 2019-07-11 Sandoz Ag Encapsulated particles comprising a pharmaceutically active ingredient
MX2021010692A (es) * 2019-03-04 2021-10-01 Japan Tobacco Inc Dispersion solida amorfa de compuesto de pirazol-amida.
EP4021450B1 (en) * 2019-08-26 2025-11-05 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
EP4211128A1 (en) 2020-09-14 2023-07-19 Arvinas Operations, Inc. Crystalline forms of a compound for the targeted degradation of estrogen receptor
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
BRPI0415935A (pt) * 2003-10-27 2007-01-02 Vertex Pharma combinações para tratamento de hcv
US8187874B2 (en) * 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
ZA200700030B (en) * 2004-06-08 2009-06-24 Vertex Pharma Pharmaceutical compositions

Similar Documents

Publication Publication Date Title
JP2009530415A5 (enExample)
JP2008501802A5 (enExample)
EP3417861B1 (en) Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
JP2009502969A5 (enExample)
TWI666020B (zh) 固體分散製劑
RU2006147247A (ru) Фармацевтические композиции
JP2009530415A (ja) 医薬組成物
WO2016038532A1 (en) Amorphous treprostinil diethanolamine
US20200261479A1 (en) Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof
EP3201191A1 (en) Complex of amorphous empagliflozin and a cyclodextrin
RU2342926C2 (ru) Способ получения низкокристаллического олтипраза или аморфного олтипраза
WO2014102628A1 (en) Stable pharmaceutical composition comprising azilsartan medoxomil
US20180228826A1 (en) Fixed-dose combinations of antiviral compounds
CN110958880B (zh) 固体分散制剂
JP2010536837A5 (enExample)
JP2019516765A5 (enExample)
CN105939715A (zh) 抗病毒化合物的固定剂量组合
JP5297194B2 (ja) 初期溶解率が改善されたプランルカスト固体分散体の薬剤学的組成物およびその製造方法
CN111297822A (zh) 一种利伐沙班微丸胶囊及其制备方法
JP2024040951A5 (enExample)
KR20190038881A (ko) 무정형 소포스부비르를 포함하는 고체 제약 조성물
CN104093400A (zh) 稳定的无定形雷特格韦钾盐预混料及其制备方法
JP2016538312A (ja) 非晶質のコビシスタットの固体分散体
KR101238042B1 (ko) 표면 부착 방식을 이용한 실리마린 고체 분산체 조성물
WO2017130219A1 (en) Amorphous solid dispersion of palbociclib